PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS
Operating Margin
PhaseBio Pharmaceuticals Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | US |
Market Cap | 2m USD |
Operating Margin |
-12 739%
|
Country | US |
Market Cap | 293.9B USD |
Operating Margin |
29%
|
Country | US |
Market Cap | 167.6B USD |
Operating Margin |
24%
|
Country | US |
Market Cap | 115B USD |
Operating Margin |
41%
|
Country | US |
Market Cap | 108.2B USD |
Operating Margin |
30%
|
Country | AU |
Market Cap | 135.3B AUD |
Operating Margin |
26%
|
Country | US |
Market Cap | 84.4B USD |
Operating Margin |
32%
|
Country | US |
Market Cap | 50.9B USD |
Operating Margin |
-100%
|
Country | US |
Market Cap | 43.1B USD |
Operating Margin |
-33%
|
Country | US |
Market Cap | 33.6B USD |
Operating Margin |
22%
|
Country | KR |
Market Cap | 39.7T KRW |
Operating Margin |
30%
|
Profitability Report
View the profitability report to see the full profitability analysis for PhaseBio Pharmaceuticals Inc.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on PhaseBio Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -12 738.6%.